S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
S&P 500   3,383.92 (+1.51%)
DOW   27,962.16 (+0.99%)
QQQ   272.58 (+2.79%)
AAPL   449.76 (+2.80%)
MSFT   208.91 (+2.72%)
FB   260.71 (+1.79%)
GOOGL   1,505.20 (+1.67%)
AMZN   3,155.67 (+2.43%)
NVDA   454.73 (+4.78%)
CGC   17.40 (+2.65%)
BABA   255.74 (+2.95%)
TSLA   1,527.24 (+11.12%)
GE   6.63 (-1.49%)
MU   48.33 (+1.19%)
AMD   82.24 (+6.97%)
T   30.20 (-0.26%)
F   7.11 (-1.66%)
ACB   9.92 (-1.00%)
GILD   68.86 (+1.12%)
NFLX   479.79 (+2.75%)
DIS   131.35 (+0.66%)
BAC   26.56 (-1.34%)
BA   173.96 (-3.43%)
Log in

NYSE:NVONovo Nordisk A/S Stock Price, Forecast & News

$67.14
+1.95 (+2.99 %)
(As of 08/12/2020 02:14 PM ET)
Add
Compare
Today's Range
$66.37
Now: $67.14
$67.55
50-Day Range
$63.69
MA: $66.11
$68.51
52-Week Range
$48.60
Now: $67.14
$68.96
Volume31,897 shs
Average Volume1.71 million shs
Market Capitalization$158.10 billion
P/E Ratio25.72
Dividend Yield1.73%
Beta0.43
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has a collaboration agreement Lund University to develop stem cell-derived treatment for Parkinson's diseases; and Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Read More
Novo Nordisk A/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.0Community Rank: 2.2Dividend Strength: 2.5Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.80 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.30 billion
Cash Flow$2.93 per share
Book Value$3.65 per share

Profitability

Net Income$5.84 billion

Miscellaneous

Employees43,258
Outstanding Shares2,354,800,000
Market Cap$158.10 billion
Next Earnings Date11/6/2020 (Estimated)
OptionableOptionable
$67.14
+1.95 (+2.99 %)
(As of 08/12/2020 02:14 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

How has Novo Nordisk A/S's stock been impacted by COVID-19 (Coronavirus)?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, NVO stock has increased by 16.0% and is now trading at $67.14.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Novo Nordisk A/S?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 2 sell ratings, 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Novo Nordisk A/S
.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Novo Nordisk A/S
.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) posted its quarterly earnings data on Wednesday, May, 6th. The company reported $0.75 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.68 by $0.07. The company earned $5 billion during the quarter, compared to the consensus estimate of $4.70 billion. Novo Nordisk A/S had a net margin of 32.73% and a return on equity of 73.42%.
View Novo Nordisk A/S's earnings history
.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S declared a semi-annual dividend on Friday, August 7th. Investors of record on Monday, August 17th will be paid a dividend of $0.7826 per share on Tuesday, August 25th. This represents a dividend yield of 1.4%. The ex-dividend date of this dividend is Friday, August 14th.
View Novo Nordisk A/S's dividend history
.

What price target have analysts set for NVO?

12 equities research analysts have issued 1-year price targets for Novo Nordisk A/S's shares. Their forecasts range from $72.00 to $400.00. On average, they expect Novo Nordisk A/S's share price to reach $236.00 in the next twelve months. This suggests a possible upside of 251.5% from the stock's current price.
View analysts' price targets for Novo Nordisk A/S
.

Has Novo Nordisk A/S been receiving favorable news coverage?

Media stories about NVO stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a media sentiment score of -2.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.
View the latest news about Novo Nordisk A/S
.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a drop in short interest in the month of February. As of February 15th, there was short interest totaling 5,210,000 shares, a drop of 13.7% from the January 31st total of 6,040,000 shares. Based on an average daily volume of 1,340,000 shares, the short-interest ratio is presently 3.9 days. Currently, 0.3% of the shares of the stock are sold short.
View Novo Nordisk A/S's Short Interest
.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include AbbVie (ABBV), Gilead Sciences (GILD), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), QUALCOMM (QCOM), Cisco Systems (CSCO), AT&T (T) and Abbott Laboratories (ABT).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
  • Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
  • Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a number of retail and institutional investors. Top institutional investors include Fisher Asset Management LLC (0.66%), Everett Harris & Co. CA (0.14%), Saratoga Research & Investment Management (0.05%), Envestnet Asset Management Inc. (0.05%), Raymond James & Associates (0.05%) and Natixis Advisors L.P. (0.05%).
View institutional ownership trends for Novo Nordisk A/S
.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Natixis Advisors L.P., Saratoga Research & Investment Management, Raymond James & Associates, Jennison Associates LLC, Russell Investments Group Ltd., Scout Investments Inc., QV Investors Inc., and Parsec Financial Management Inc..
View insider buying and selling activity for Novo Nordisk A/S
.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was bought by a variety of institutional investors in the last quarter, including Thrivent Financial for Lutherans, Fisher Asset Management LLC, Calamos Advisors LLC, Cullen Frost Bankers Inc., Envestnet Asset Management Inc., Raymond James Financial Services Advisors Inc., Hardman Johnston Global Advisors LLC, and Everett Harris & Co. CA.
View insider buying and selling activity for Novo Nordisk A/S
.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $67.14.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $158.10 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 43,258 workers across the globe.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is www.novonordisk.com.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.